AstraZeneca (AZN) Withdraws App for Ovarian-Cancer Treatment in Europe
- Top 10 News for 12/2: Crude Rips on OPEC Cut; Starbucks' Schultz Steps Down; Nonfarm Payrolls Flat in Nov.
- Unemployment Rate Drops to 4.6%
- Bond yields slip on U.S. jobs data, euro steady before Italy vote
- Alibaba (BABA) Founder Jack Ma Discuss Plans to Retire; 'I Don't Want to Die at the Office'
- Starbucks Coffee (SBUX) CEO Howard Schultz to Step Down, Appointed Executive Chairman; Kevin Johnson New CEO
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
AstraZeneca (NYSE: AZN) is said to have withdrawn its application for approval of cediranib in Europe following a disagreement with regulators.
Bloomberg noted that the action won't affect development of the ovarian cancer treatment.
AstraZeneca filed an application with the European Medicines Agency in June 2015 seeking approval of cediranib for use with platinum-based chemotherapy in adults with a type of ovarian cancer that’s relapsed.
Shares of AstraZeneca are indicated lower Wednesday morning.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MedImmune and Abpro Enter Into a Collaborative Agreement for a Novel Bispecific Antibody
- AstraZeneca's (AZN) MedImmune and Abpro Enter Novel Bispecific Antibody Development Agreement
- Options with increasing volume
Create E-mail Alert Related CategoriesFDA, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!